Work

Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML

Year: 2017

Type: article

Source: Blood

DOI: 10.1182/blood.v130.suppl_1.2684.2684

Authors: Richard M. Stone, Sung Choe, Vickie Zhang, Benoît Marteyn, Virginie Penard‐Lacronique, Hongfang Wang, Courtney D. DiNardo, Eytan M. Stein, Amir T. Fathi, Martin S. Tallman, Hagop M. Kantarjian, Eyal C. Attar, Bin Wu, Stéphane de Botton

Institutions: Dana-Farber Cancer Institute, Agios Pharmaceuticals (United States), Institut Pasteur, Inserm, Université Paris-Saclay, Institut Gustave Roussy, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3134473046

FWCI: 0.181

Cites:

Cited by: 1

Related to: 20